These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14742668)

  • 1. Lessons from the CYP3A4 promoter.
    Schuetz EG
    Mol Pharmacol; 2004 Feb; 65(2):279-81. PubMed ID: 14742668
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations.
    Reyes-Hernández OD; Lares-Asseff I; Sosa-Macias M; Vega L; Albores A; Elizondo G
    Pharmacology; 2008; 81(2):97-103. PubMed ID: 17952011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
    Garsa AA; McLeod HL; Marsh S
    BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
    Keshava C; McCanlies EC; Weston A
    Am J Epidemiol; 2004 Nov; 160(9):825-41. PubMed ID: 15496535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel polymorphic enhancer of the human CYP3A4 gene.
    Matsumura K; Saito T; Takahashi Y; Ozeki T; Kiyotani K; Fujieda M; Yamazaki H; Kunitoh H; Kamataki T
    Mol Pharmacol; 2004 Feb; 65(2):326-34. PubMed ID: 14742674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of MboII polymorphism at the 5' promoter region of CYP3A4.
    Cavalli SA; Hirata MH; Hirata RD
    Clin Chem; 2001 Feb; 47(2):348-51. PubMed ID: 11159790
    [No Abstract]   [Full Text] [Related]  

  • 7. Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP. Distribution frequencies in a Mexican population.
    Reyes-Hernández OD; Arteaga-Illán G; Elizondo G
    Clin Genet; 2004 Aug; 66(2):166-8. PubMed ID: 15253768
    [No Abstract]   [Full Text] [Related]  

  • 8. MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa.
    Chelule PK; Gordon M; Palanee T; Page T; Mosam A; Coovadia HM; Cassol S
    Clin Pharmacol Ther; 2003 Aug; 74(2):195-6. PubMed ID: 12891231
    [No Abstract]   [Full Text] [Related]  

  • 9. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations.
    Tayeb MT; Clark C; Ameyaw MM; Haites NE; Evans DA; Tariq M; Mobarek A; Ofori-Adjei D; McLeod HL
    Pharmacogenetics; 2000 Nov; 10(8):753-6. PubMed ID: 11186137
    [No Abstract]   [Full Text] [Related]  

  • 10. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
    Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M
    Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.
    Rodríguez-Antona C; Sayi JG; Gustafsson LL; Bertilsson L; Ingelman-Sundberg M
    Biochem Biophys Res Commun; 2005 Dec; 338(1):299-305. PubMed ID: 16171783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping of the A6986G polymorphism of CYP3A5.
    Weiss J; Haefeli WE
    Br J Clin Pharmacol; 2004 May; 57(5):663; author reply 664. PubMed ID: 15089823
    [No Abstract]   [Full Text] [Related]  

  • 13. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
    Wang J
    Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials.
    Foti RS; Fisher MB
    Pharmacogenomics J; 2004; 4(6):362-4. PubMed ID: 15483658
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of human pregnane X receptor involvement in pesticide-mediated activation of CYP3A4 gene.
    Matsubara T; Noracharttiyapot W; Toriyabe T; Yoshinari K; Nagata K; Yamazoe Y
    Drug Metab Dispos; 2007 May; 35(5):728-33. PubMed ID: 17293382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased transcriptional activity of the CYP3A4*1B promoter variant.
    Amirimani B; Ning B; Deitz AC; Weber BL; Kadlubar FF; Rebbeck TR
    Environ Mol Mutagen; 2003; 42(4):299-305. PubMed ID: 14673875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha.
    Liu FJ; Song X; Yang D; Deng R; Yan B
    Biochem J; 2008 Jan; 409(1):243-50. PubMed ID: 17764444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations.
    Du J; Yu L; Wang L; Zhang A; Shu A; Xu L; Xu M; Shi Y; Li X; Feng G; Xing Q; He L
    Clin Chim Acta; 2007 Aug; 383(1-2):172-4. PubMed ID: 17582393
    [No Abstract]   [Full Text] [Related]  

  • 19. CYP3A phenotypes and genotypes in North Indians.
    Rais N; Chawla YK; Kohli KK
    Eur J Clin Pharmacol; 2006 Jun; 62(6):417-22. PubMed ID: 16758258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia.
    Collado M; Barragan E; Bolufer P; Calasanz MJ; Larrayoz MJ; Colomer D; Munarriz B; Verdeguer A; Gutierrez A; Batlle M; Sanz MA
    Leuk Res; 2005 May; 29(5):595-7. PubMed ID: 15755514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.